Pfizer's Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment on April 14, 2025 danuglipron GLP-1 receptor GLP-1/GIP therapies Injury of liver Metabolic Diseases Obesity Pfizer pharmaceutical competition pipeline Weight-Loss Agents +